These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

363 related articles for article (PubMed ID: 26759327)

  • 21. Inflammation and oxidative stress in diabetic nephropathy: new insights on its inhibition as new therapeutic targets.
    Mima A
    J Diabetes Res; 2013; 2013():248563. PubMed ID: 23862164
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Recent advances in understanding the biochemical and molecular mechanism of diabetic nephropathy.
    Sun YM; Su Y; Li J; Wang LF
    Biochem Biophys Res Commun; 2013 Apr; 433(4):359-61. PubMed ID: 23541575
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Therapeutic strategies of diabetic nephropathy: recent progress and future perspectives.
    Lv M; Chen Z; Hu G; Li Q
    Drug Discov Today; 2015 Mar; 20(3):332-46. PubMed ID: 25448752
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Molecular mechanism of diabetic nephropathy].
    Ohshiro Y; Takasu N
    Nihon Rinsho; 2006 May; 64(5):997-1003. PubMed ID: 16689387
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Determination of oxidative stress and cellular inflammation in patients with diabetic nephropathy and non-diabetic nephropathy being administered hemodialysis treatment due to chronic renal failure.
    Avci E; Cakir E; Cevher SC; Yaman H; Agilli M; Bilgi C
    Ren Fail; 2014 Jun; 36(5):767-73. PubMed ID: 24579657
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Urotensin-II level and its association with oxidative stress in early diabetic nephropathy.
    Tabur S; Korkmaz H; Eren MA; Oğuz E; Sabuncu T; Aksoy N
    J Diabetes Complications; 2015; 29(1):115-9. PubMed ID: 25179234
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Depiction of immune heterogeneity of peripheral blood from patients with type II diabetic nephropathy based on mass cytometry.
    Jin J; Wang L; Liu Y; He W; Zheng D; Ni Y; He Q
    Front Endocrinol (Lausanne); 2022; 13():1018608. PubMed ID: 36686486
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Proteomics and diabetic nephropathy.
    Merchant ML; Klein JB
    Curr Diab Rep; 2005 Dec; 5(6):464-9. PubMed ID: 16316599
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Development of Biomarkers and Molecular Therapy Based on Inflammatory Genes in Diabetic Nephropathy.
    Maiti AK
    Int J Mol Sci; 2021 Sep; 22(18):. PubMed ID: 34576149
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Exosomes: Advances, development and potential therapeutic strategies in diabetic nephropathy.
    Chen J; Zhang Q; Liu D; Liu Z
    Metabolism; 2021 Sep; 122():154834. PubMed ID: 34217734
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Research progress in signalling pathway in diabetic nephropathy.
    Ni WJ; Tang LQ; Wei W
    Diabetes Metab Res Rev; 2015 Mar; 31(3):221-33. PubMed ID: 24898554
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Sphingosine Kinase-1/sphingosine 1-phosphate pathway in diabetic nephropathy.
    Deng Y; Lan T; Huang J; Huang H
    Chin Med J (Engl); 2014; 127(16):3004-10. PubMed ID: 25131242
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Twenty years after ACEIs and ARBs: emerging treatment strategies for diabetic nephropathy.
    Johnson SA; Spurney RF
    Am J Physiol Renal Physiol; 2015 Nov; 309(10):F807-20. PubMed ID: 26336162
    [TBL] [Abstract][Full Text] [Related]  

  • 34. JDRF perspective: bridging the gap-translational research to prevent progression of diabetic nephropathy.
    Nickerson HD; Dutta S
    Semin Nephrol; 2012 Sep; 32(5):512-6. PubMed ID: 23062993
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Aryl Hydrocarbon Receptor Deficiency Attenuates Oxidative Stress-Related Mesangial Cell Activation and Macrophage Infiltration and Extracellular Matrix Accumulation in Diabetic Nephropathy.
    Lee WJ; Liu SH; Chiang CK; Lin SY; Liang KW; Chen CH; Tien HR; Chen PH; Wu JP; Tsai YC; Lai DW; Chang YC; Sheu WH; Sheu ML
    Antioxid Redox Signal; 2016 Feb; 24(4):217-231. PubMed ID: 26415004
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Metabolomics in diabetic nephropathy: Unveiling novel biomarkers for diagnosis (Review).
    Luo Y; Zhang W; Qin G
    Mol Med Rep; 2024 Sep; 30(3):. PubMed ID: 38963028
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Role of oxidative stress in diabetic nephropathy.
    Vasavada N; Agarwal R
    Adv Chronic Kidney Dis; 2005 Apr; 12(2):146-54. PubMed ID: 15822050
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Novel biomarkers for diabetic nephropathy].
    Araki S
    Rinsho Byori; 2014 Feb; 62(2):171-9. PubMed ID: 24800493
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tropisetron ameliorates early diabetic nephropathy in streptozotocin-induced diabetic rats.
    Barzegar-Fallah A; Alimoradi H; Asadi F; Dehpour AR; Asgari M; Shafiei M
    Clin Exp Pharmacol Physiol; 2015 Apr; 42(4):361-8. PubMed ID: 25676798
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Allelic variations in the CYBA gene of NADPH oxidase and risk of kidney complications in patients with type 1 diabetes.
    Patente TA; Mohammedi K; Bellili-Muñoz N; Driss F; Sanchez M; Fumeron F; Roussel R; Hadjadj S; Corrêa-Giannella ML; Marre M; Velho G
    Free Radic Biol Med; 2015 Sep; 86():16-24. PubMed ID: 25862415
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.